<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xml:lang="EN" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="brief-report">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">Front. Pediatr.</journal-id>
<journal-title>Frontiers in Pediatrics</journal-title>
<abbrev-journal-title abbrev-type="pubmed">Front. Pediatr.</abbrev-journal-title>
<issn pub-type="epub">2296-2360</issn>
<publisher>
<publisher-name>Frontiers Media S.A.</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.3389/fped.2022.876882</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Pediatrics</subject>
<subj-group>
<subject>Brief Research Report</subject>
</subj-group>
</subj-group>
</article-categories>
<title-group>
<article-title>TLR4 Gene Polymorphisms Interaction With <italic>Ascaris</italic> Infection in Severe RSV Bronchiolitis</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" corresp="yes">
<name><surname>Buend&#x000ED;a</surname> <given-names>Jefferson Antonio</given-names></name>
<xref ref-type="aff" rid="aff1"><sup>1</sup></xref>
<xref ref-type="corresp" rid="c001"><sup>&#x0002A;</sup></xref>
<uri xlink:href="http://loop.frontiersin.org/people/993808/overview"/>
</contrib>
<contrib contrib-type="author">
<name><surname>Lindarte</surname> <given-names>Erika Fernanda</given-names></name>
<xref ref-type="aff" rid="aff1"><sup>1</sup></xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Polack</surname> <given-names>Fernando P.</given-names></name>
<xref ref-type="aff" rid="aff2"><sup>2</sup></xref>
<uri xlink:href="http://loop.frontiersin.org/people/658708/overview"/>
</contrib>
</contrib-group>
<aff id="aff1"><sup>1</sup><institution>Department of Pharmacology and Toxicology, School of Medicine, Research Group in Pharmacology and Toxicology (INFARTO), Universidad de Antioquia</institution>, <addr-line>Medell&#x000ED;n</addr-line>, <country>Colombia</country></aff>
<aff id="aff2"><sup>2</sup><institution>Fundacion Infant</institution>, <addr-line>Buenos Aires</addr-line>, <country>Argentina</country></aff>
<author-notes>
<fn fn-type="edited-by"><p>Edited by: Diego Raul Hijano, St. Jude Children&#x00027;s Research Hospital, United States</p></fn>
<fn fn-type="edited-by"><p>Reviewed by: Fernando Ferrero, Hospital Pedro de Elizalde, Argentina; Alessandra Pierangeli, Sapienza University of Rome, Italy; Diana Guerrero, Hospital Materno-Infantil, Spain</p></fn>
<corresp id="c001">&#x0002A;Correspondence: Jefferson Antonio Buend&#x000ED;a <email>jefferson.buendia&#x00040;gmail.com</email></corresp>
<fn fn-type="other" id="fn001"><p>This article was submitted to Pediatric Pulmonology, a section of the journal Frontiers in Pediatrics</p></fn></author-notes>
<pub-date pub-type="epub">
<day>27</day>
<month>04</month>
<year>2022</year>
</pub-date>
<pub-date pub-type="collection">
<year>2022</year>
</pub-date>
<volume>10</volume>
<elocation-id>876882</elocation-id>
<history>
<date date-type="received">
<day>16</day>
<month>02</month>
<year>2022</year>
</date>
<date date-type="accepted">
<day>29</day>
<month>03</month>
<year>2022</year>
</date>
</history>
<permissions>
<copyright-statement>Copyright &#x000A9; 2022 Buend&#x000ED;a, Lindarte and Polack.</copyright-statement>
<copyright-year>2022</copyright-year>
<copyright-holder>Buend&#x000ED;a, Lindarte and Polack</copyright-holder>
<license xlink:href="http://creativecommons.org/licenses/by/4.0/"><p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</p></license> </permissions>
<abstract>
<sec>
<title>Introduction</title>
<p>The identification of gene-environment interactions allows the recognition of groups with higher risk of morbidity. This study evaluated the interaction between the presence of TLR4 gene polymorphisms and <italic>Ascaris</italic> infection with severe bronchiolitis in a tropical Colombian region.</p></sec>
<sec>
<title>Methods</title>
<p>We included all infants younger than 24 months hospitalized due to bronchiolitis in Hospital centers in the county of Rionegro, Colombia. To identify interaction between severe bronchiolitis and presence of TLR4 polymorphisms and <italic>Ascaris</italic> infection, we used log-binomial regression.</p></sec>
<sec>
<title>Results</title>
<p>Four hundred and seventeen infants were hospitalized due to bronchiolitis, of which 115 (27%) had severe bronchiolitis. In infants with respiratory syncytial virus (RSV) acute infection and positive anti-Ascaris IgE, TLR4 Asp299Gly was associated to low risk of severe bronchiolitis (OR 0.09, CI 95% 0.01&#x02013;0.48). Conversely, in infants RSV negative with negative anti-Ascaris IgE, TLR4 Asp299Gly was associated with an increased risk of severe bronchiolitis (OR 14.5, CI 95% 2.2&#x02013;96).</p></sec>
<sec>
<title>Conclusion</title>
<p>In our population there is an interaction between the presence of severe bronchiolitis, TLR4 Asp299Gly and Ile399Thr polymorphisms, anti-Ascaris IgE levels and RSV. This association should be evaluated in other populations to elucidate its role in the pathogenesis of severe bronchiolitis.</p></sec></abstract>
<kwd-group>
<kwd>severe bronchiolitis</kwd>
<kwd>polymorphism</kwd>
<kwd>respiratory syncytial virus</kwd>
<kwd><italic>Ascaris</italic>. suum</kwd>
<kwd>Colombia</kwd>
</kwd-group>
<counts>
<fig-count count="0"/>
<table-count count="2"/>
<equation-count count="0"/>
<ref-count count="16"/>
<page-count count="4"/>
<word-count count="2913"/>
</counts>
</article-meta>
</front>
<body>
<sec sec-type="intro" id="s1">
<title>Introduction</title>
<p>Respiratory syncytial virus (RSV) bronchiolitis is the most important cause of lower respiratory tract infection in children worldwide (<xref ref-type="bibr" rid="B1">1</xref>, <xref ref-type="bibr" rid="B2">2</xref>). The disease places a substantial clinical and economic burden, not only on healthcare systems, but also on families and society, mainly in low-to- middle-income countries (LMICs) where more than 90% of the deaths occur (<xref ref-type="bibr" rid="B3">3</xref>&#x02013;<xref ref-type="bibr" rid="B6">6</xref>). The treatment consists only in respiratory and hemodynamical support since there is no a specific intervention or vaccination yet (<xref ref-type="bibr" rid="B7">7</xref>). Identifying patients at higher risk of morbidity and mortality is essential to plan preemptive strategies in the future. Different determinants of bronchiolitis severity have been described, among them RSV infection, smoking, pre-existing diseases, absence of breastfeeding (<xref ref-type="bibr" rid="B8">8</xref>).</p>
<p>A gene-environment interaction as documented between toll like receptor 4 (TLR4) D299G single nucleotide polymorphism and environmental endotoxin exposure reveals a possible T helper 2 (Th2) polarizations in patients with severe RSV bronchiolitis, which may become useful for early identification of these patients at risk of severe RSV disease (<xref ref-type="bibr" rid="B9">9</xref>). However, in tropical countries, in addition to exposure to endotoxin, the presence of <italic>Ascaris lumbricoides</italic> infection has been associated with a Th2 profile in asthmatic or recurrent wheezing children (<xref ref-type="bibr" rid="B10">10</xref>). Although, both environmental stimuli may share similar immunological pathways, the gene-environment interaction between TLR4 polymorphisms and infection with <italic>A. lumbricoides</italic> has not been evaluated. Previously, we made a first report analyzing clinical and sociodemographic risk factors associated with severe bronchiolitis in a retrospective cohort of children with bronchiolitis &#x0003C;2 years of age in Rionegro, Colombia (<xref ref-type="bibr" rid="B8">8</xref>). In this study and, using the same population, we study aimed to evaluate the association between the presence of RSV bronchiolitis with TRL4 polymorphisms and <italic>Ascaris</italic> infection in infants under 2 years old.</p>
</sec>
<sec sec-type="methods" id="s2">
<title>Methods</title>
<p>The methodology and characteristics of this population were reported previously (<xref ref-type="bibr" rid="B8">8</xref>). We included all children with bronchiolitis &#x0003C;2 years old in two hospital centers in the municipality of Rionegro Colombia, between January 2019 to December 2019. All infants diagnosed with bronchiolitis, according to the national clinical guideline of bronchiolitis, were included (<xref ref-type="bibr" rid="B8">8</xref>). We excluded infants who did not present lower respiratory infection or positive bacterial cultures on admission or confirmed whooping cough. The Institutional Review Board of the University of Antioquia approved the study protocol (No. 18/2015).</p>
<p>We collected sociodemographic, medical, and clinical variables from medical records in the hospital centers. All variables that were not fully documented in the clinical history were obtained by directly interviewing the parents or caregivers in person or by telephone, previous informed consent to the responsible for the children. Severe bronchiolitis was identified in patients who had an increased respiratory rate, retractions, and oxygen saturation of 90% or less (<xref ref-type="bibr" rid="B11">11</xref>). Nasopharyngeal aspirate (NPA) was taken during the first 48 h in the emergency unit using a standardized technique. RSV was confirmed using direct immunofluorescence. There was no data available for other viruses. ImmunoCAP (Thermo Fisher Scientific) was used to measure the levels of specific IgE antibodies against <italic>Ascaris</italic> spp. where it was considered positive when the specific IgE levels were equal to or greater than 0.35 kUA/L. DNA was obtained from whole blood samples using the Gentra Puregene kit (Gentra Systems) and DNA was quantified using a Beckman Coulter DU640 spectrophotometer. The REPLI-g kit (QIAGEN) was used for the amplification of the DNA samples. The TLR4 Asp299Gly and Ile399Thr polymorphisms were evaluated by allelic discrimination using Applied Biosystems assays that had probes with specific fluorophores for each of the polymorphisms. The thermal profile for PCR consisted of an initial denaturation at 95&#x000B0;C for 10 min, followed by 35 cycles at 92&#x000B0;C for 15 s and 60&#x000B0;C for 1 min. An ABI 7000 (Applied Biosystems) was used for PCR amplification and subsequent characterization of the genotypes for each polymorphism. Controls were used for the correct identification of genotypes in patient samples.</p>
<sec>
<title>Statistical Analysis</title>
<p>We analyzed the differences of continuous variables using the unpaired <italic>t</italic>-test or Wilcoxon&#x00027;s signed-rank test, whichever was appropriate, categorical variables were analyzed using the chi-square test or Fisher&#x00027;s exact test. We included only in the final model variables associated with severe bronchiolitis with values of <italic>P</italic> &#x0003C; 0.2 or that changed the effect estimate by over 10% after their inclusion, to identify factors independently associated with severe bronchiolitis. We also included in the model variables widely known and related to severe bronchiolitis such as age, smoking at home and exclusive breastfeeding (<xref ref-type="bibr" rid="B8">8</xref>, <xref ref-type="bibr" rid="B12">12</xref>). A log-binomial regression model was performed with a backward elimination method, used with a <italic>P</italic>-value of 0.05 as the limit value for the model entry (<xref ref-type="bibr" rid="B7">7</xref>). Hosmer&#x02013;Lemeshow test was used to evaluate he goodness of fit of the model. Two-tailed, and the significance level of <italic>P</italic> &#x0003C; 0.05 were used in all statistical tests were. All data were analyzed with Statistical Package Stata 15.0 (Stata Corporation, College Station, TX).</p>
</sec>
</sec>
<sec sec-type="results" id="s3">
<title>Results</title>
<sec>
<title>Population Characteristics</title>
<p>During the study period, 417 infants with bronchiolitis were included. <xref ref-type="table" rid="T1">Table 1</xref> shows the clinical characteristics of the infant population evaluated. Sixty-six percentage of the patients were &#x0003C;6 months, most of them males (60%), RSV was detected in 200 patients. TLR4 Asp299Gly (AG or AA) was present in 59 patients (14%), while TLR4 Ile399Thr (CC or CT) was present in 286 patients (68%). All the alleles of the TLR4 Asp299Gly and Ile399Thr polymorphisms were in Hardy-Weinberg equilibrium. Positive anti-Ascaris IgE levels (&#x0003E;0.35 kU/L) were observed in 74 patients (18%).</p>
<table-wrap position="float" id="T1">
<label>Table 1</label>
<caption><p>Univariate analysis of demographic features and clinical information associated with severe bronchiolitis.</p></caption>
<table frame="hsides" rules="groups">
<thead><tr>
<th valign="top" align="left"><bold>Variable. <italic>N</italic> (%)</bold></th>
<th valign="top" align="center"><bold><italic>n</italic> (%)</bold></th>
<th valign="top" align="center"><bold>OR (CI 95%)</bold></th>
</tr>
</thead>
<tbody>
<tr>
<td valign="top" align="left">Age &#x0003C;6 month</td>
<td valign="top" align="center">277 (66)</td>
<td valign="top" align="center">1.00 (0.99&#x02013;1.00)</td>
</tr>
<tr>
<td valign="top" align="left">Male, <italic>n</italic> (%)</td>
<td valign="top" align="center">251 (60)</td>
<td valign="top" align="center">1.05 (0.67&#x02013;1.62)</td>
</tr>
<tr>
<td valign="top" align="left">Premature birth</td>
<td valign="top" align="center">81 (19)</td>
<td valign="top" align="center">0.67 (0.40&#x02013;1.13)</td>
</tr>
<tr>
<td valign="top" align="left">Comorbidities (CHD or neurological)</td>
<td valign="top" align="center">20 (4.81)</td>
<td valign="top" align="center">1.57 (0.51&#x02013;4.82)</td>
</tr>
<tr>
<td valign="top" align="left">BPD</td>
<td valign="top" align="center">17 (4.09)</td>
<td valign="top" align="center">0.41 (0.15&#x02013;1.10)</td>
</tr>
<tr>
<td valign="top" align="left">Atopy</td>
<td valign="top" align="center">17 (4.09)</td>
<td valign="top" align="center">0.92 (0.31&#x02013;2.68)</td>
</tr>
<tr>
<td valign="top" align="left">Previously hospitalization by bronchiolitis</td>
<td valign="top" align="center">30 (7.21)</td>
<td valign="top" align="center">1.59 (0.63&#x02013;4.00)</td>
</tr>
<tr>
<td valign="top" align="left">Exposure to cigarette smoking</td>
<td valign="top" align="center">49 (<xref ref-type="bibr" rid="B12">12</xref>)</td>
<td valign="top" align="center">2.53 (1.10&#x02013;5.81)</td>
</tr>
<tr>
<td valign="top" align="left">Complete vaccination for age</td>
<td valign="top" align="center">415 (99)</td>
<td valign="top" align="center">0.67 (0.42&#x02013;1.11)</td>
</tr>
<tr>
<td valign="top" align="left">Exclusive maternal breastfeeding for at least 6 month</td>
<td valign="top" align="center">102 (24)</td>
<td valign="top" align="center">0.96 (0.58&#x02013;1.58)</td>
</tr>
<tr>
<td valign="top" align="left">O<sub>2</sub> supportive, <italic>n</italic> (%)</td>
<td valign="top" align="center">347 (83)</td>
<td valign="top" align="center">16.5 (8.77&#x02013;31.2)</td>
</tr>
<tr>
<td valign="top" align="left">Leucocytosis (&#x0003E;15,000/mm<sup>3</sup>)</td>
<td valign="top" align="center">51 (<xref ref-type="bibr" rid="B12">12</xref>)</td>
<td valign="top" align="center">1.02 (0.53&#x02013;1.97)</td>
</tr>
<tr>
<td valign="top" align="left">RSV positive</td>
<td valign="top" align="center">200 (48)</td>
<td valign="top" align="center">1.77 (1.14&#x02013;2.74)</td>
</tr>
<tr>
<td valign="top" align="left">TLR4 rs4986790 (AG/GG)</td>
<td valign="top" align="center">59 (<xref ref-type="bibr" rid="B13">13</xref>)</td>
<td valign="top" align="center">0.84 (0.47&#x02013;1.51)</td>
</tr>
<tr>
<td valign="top" align="left">TLR4 rs4986791 (CT/TT)</td>
<td valign="top" align="center">286 (68)</td>
<td valign="top" align="center">1.10 (0.71&#x02013;1.73)</td>
</tr>
<tr>
<td valign="top" align="left">Positive anti-Ascaris IgE levels (&#x0003E;0.35 kU/L)</td>
<td valign="top" align="center">74 (18)</td>
<td valign="top" align="center">2.79 (1.58&#x02013;4.92)</td>
</tr>
<tr>
<td valign="top" align="left">Increased C-reactive protein (&#x0003E;4 mg/L)</td>
<td valign="top" align="center">327 (78)</td>
<td valign="top" align="center">1.76 (0.97&#x02013;3.20)</td>
</tr>
<tr>
<td valign="top" align="left">Length of hospital stay, median (range)</td>
<td valign="top" align="center">3.68 (0.74&#x02013;29)</td>
<td valign="top" align="center">1.02 (0.98 1.07)</td>
</tr>
<tr>
<td valign="top" align="left">PICU</td>
<td valign="top" align="center">55 (<xref ref-type="bibr" rid="B14">14</xref>)</td>
<td valign="top" align="center">0.93 (0.49&#x02013;1.74)</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<p><italic>CHD, congenital heart disease; BPD, bronchopulmonary dysplasia; PICU, pediatric intensive care unit admission; RSV, respiratory syncytial virus</italic>.</p>
</table-wrap-foot>
</table-wrap>
<sec>
<title>Univariable Analysis</title>
<p>Among all 417 infants, 115 (27%) had severe bronchiolitis. Exposure to smoking in home (OR 2.53, CI 95%, 1.10&#x02013;5.81), positive anti-Ascaris IgE levels (OR 2.79, CI 95% 1.58&#x02013;4.92), RSV (OR 1.77, CI 95% 1.14&#x02013;2.74), crepitation 3.06 (OR, CI 95% 1.19&#x02013;5.23), and pneumonia (OR 2.54, CI 95% 1.31&#x02013;4.89) were associated with severe bronchiolitis, <xref ref-type="table" rid="T1">Table 1</xref>.</p>
</sec>
<sec>
<title>Multivariable Analysis</title>
<p>After modeling, we detected a statistically significant interaction between severe bronchiolitis and TRL4-IgE Ascaris in RSV-positive (<italic>P</italic> = 0.000) and non-RSV-positive children (<italic>P</italic> = 0.000). In infants with positive anti-Ascaris IgE levels, TLR4 Asp299Gly was associated with low risk of severe bronchiolitis independent of the presence or absence of RSV infection. Conversely, in infants with negative anti-Ascaris IgE levels, TLR4 Asp299Gly was associated with higher risk of severe bronchiolitis independent of the presence or absence of RSV infection (see <xref ref-type="table" rid="T2">Table 2</xref>).</p>
<table-wrap position="float" id="T2">
<label>Table 2</label>
<caption><p>OR for severe bronchiolitis: association with TLR4 mutation according to anti-Ascaris IgE Levels and RSV.</p></caption>
<table frame="hsides" rules="groups">
<thead><tr>
<th valign="top" align="left"><bold>Environment</bold></th>
<th valign="top" align="left"><bold>SNP Asp299Gly</bold></th>
<th valign="top" align="center"><bold><italic>n</italic>/<italic>N</italic> (%)</bold></th>
<th valign="top" align="center"><bold>Crude</bold></th>
<th valign="top" align="center"><bold>Adjusted&#x0002A;</bold></th>
<th valign="top" align="center"><bold><italic>P</italic>-Value</bold></th>
<th valign="top" align="center"><bold><italic>P</italic>-Value&#x0002A;&#x0002A;</bold></th>
</tr>
<tr>
<th/>
<th/>
<th/>
<th valign="top" align="center" colspan="2" style="border-top: thin solid #000000;"><bold>OR (CI 95%)</bold></th>
<th/>
<th/>
</tr>
</thead>
<tbody>
<tr>
<td valign="top" align="left" colspan="7"><bold>RSV positive</bold></td>
</tr>
<tr>
<td valign="top" align="left">Positive anti-Ascaris IgE levels</td>
<td valign="top" align="left">Yes</td>
<td valign="top" align="center">2/128 (1.5%)</td>
<td valign="top" align="center">0.09 (0.01&#x02013;0.50)</td>
<td valign="top" align="center">0.09 (0.01&#x02013;0.48)</td>
<td valign="top" align="center">0.005</td>
<td/>
</tr>
<tr>
<td/>
<td valign="top" align="left">No</td>
<td valign="top" align="center">126/128 (98.5%)</td>
<td valign="top" align="center">1.00</td>
<td valign="top" align="center">1.00</td>
<td/>
<td valign="top" align="center">&#x0003C;0.001</td>
</tr>
<tr>
<td valign="top" align="left">Negative anti-Ascaris IgE levels</td>
<td valign="top" align="left">Yes</td>
<td valign="top" align="center">16 /26 (61.5%)</td>
<td valign="top" align="center">3.22 (0.25&#x02013;40)</td>
<td valign="top" align="center">2.88 (0.14&#x02013;57)</td>
<td valign="top" align="center">0.488</td>
<td/>
</tr>
<tr>
<td/>
<td valign="top" align="left">No</td>
<td valign="top" align="center">10/26 (38.5%)</td>
<td valign="top" align="center">1.00</td>
<td valign="top" align="center">1.00</td>
<td/>
<td/>
</tr>
<tr>
<td valign="top" align="left" colspan="7"><bold>RSV negative</bold></td>
</tr>
<tr>
<td valign="top" align="left">Positive anti-Ascaris IgE levels</td>
<td valign="top" align="left">Yes</td>
<td valign="top" align="center">2/102 (2%)</td>
<td valign="top" align="center">0.05 (0.07&#x02013;0.46)</td>
<td valign="top" align="center">0.04 (0.05&#x02013;0.48)</td>
<td valign="top" align="center">0.005</td>
<td/>
</tr>
<tr>
<td/>
<td valign="top" align="left">No</td>
<td valign="top" align="center">100/102 (98%)</td>
<td valign="top" align="center">1.00</td>
<td valign="top" align="center">1.00</td>
<td/>
<td valign="top" align="center">&#x0003C;0.001</td>
</tr>
<tr>
<td valign="top" align="left">Negative anti-Ascaris IgE levels</td>
<td valign="top" align="left">Yes</td>
<td valign="top" align="center">24 /33 (72.7%)</td>
<td valign="top" align="center">13 (2.43&#x02013;73)</td>
<td valign="top" align="center">14.5 (2.20&#x02013;96)</td>
<td valign="top" align="center">0.005</td>
<td/>
</tr>
<tr>
<td/>
<td valign="top" align="left">No</td>
<td valign="top" align="center">9/33 (27.3%)</td>
<td valign="top" align="center">1.00</td>
<td valign="top" align="center">1.00</td>
<td/>
<td/>
</tr>
</tbody>
</table>
<table-wrap-foot>
<p><italic>&#x0002A;Logistic regression model, adjusted for age, smoking at home, exclusive maternal breastfeeding for at least 6 month</italic>.</p>
<p><italic>&#x0002A;&#x0002A;For interaction between TLR4 mutation and anti-Ascaris IgE levels</italic>.</p>
</table-wrap-foot>
</table-wrap>
</sec>
</sec>
</sec>
<sec sec-type="discussion" id="s4">
<title>Discussion</title>
<p>Our study identifies an interaction between severe bronchiolitis, TRL4, anti-Ascaris IgE levels and RSV. This interaction has been previously reported with bacterial endotoxin exposure (<xref ref-type="bibr" rid="B14">14</xref>). Caballero et al. (<xref ref-type="bibr" rid="B9">9</xref>), reported a significant association between TLR4 Asp299Gly and the environment with different levels of endotoxins even after adjusting for risk factors that have an effect on the severity of RSV bronchiolitis. In this study patients with high endotoxin levels, TLR4 Asp299Gly mutation was associated with less risk of severe bronchiolitis (OR 0.20 CI 95% 0.06&#x02013;0.64), while in infants with low endotoxin levels there was a tendency of higher risk of severe bronchiolitis (OR 8.96 CI 95% 0.98&#x02013;81.6). In our study we observed a similar result with anti-Ascaris IgE levels. Previously evidence has demonstrated that <italic>A. lumbricoides</italic> induces an enhanced Th2-biased immune response that cause symptoms in susceptible individuals mediated by cross-reactivity among components of both sources intensifies the Th2 response associated to allergens such as tropomyosins (<xref ref-type="bibr" rid="B13">13</xref>).</p>
<p><italic>Ascaris lumbricoides</italic> induce the adaptive immune response through its interaction with the extracellular domain of the TLR4 receptor(cite). Our study shows that this effect is regulated by the presence of variants in the TLR4 gene, such as TLR4 Asp299Gly which have been associated with a loss of function of this receptor in the plasma membrane according to previous studies (<xref ref-type="bibr" rid="B15">15</xref>). Caballero revealed that children with severe RSV exhibited a high GATA3/T-bet levels, which manifested as a high IL-4/IFN-&#x003B3; in respiratory secretions. The IL-4/IFN-&#x003B3; present in children with severe RSV is indicative of Th2 polarization. Murine models of RSV infection showed that endotoxin exposure, the Tlr4 genotype, and Th2 cell polarization influence disease phenotypes (<xref ref-type="bibr" rid="B9">9</xref>). Due to the similarity of the findings, it is possible that the mechanisms by which the bacterial endotoxin generates this antagonistic interaction are the same as those occurring in Ascaris infection, a hypothesis to be studied further.</p>
<p>Our study has some limitations. We were unable to include other variables such as environmental pollution and other genetic factors considered important for susceptibility to the disease, and residual confounding cannot be excluded. Second, the study was conducted in a reference hospital center, so the patients included represent the high spectrum of severity. Despite the above, the similarity of our population regarding clinical characteristics, risk factors and seasonality of bronchiolitis in our country coincides with the characteristics of other populations also evaluated for this disease, which suggests strength and consistency in our results (<xref ref-type="bibr" rid="B16">16</xref>). Given the retrospective nature would be possible bias due to missing data. However, in all patients the data was collected in electronic records or directly to the patient in outpatient consultations that these patients have in the hospital after their hospitalization. We concluded that in our population there is an interaction between the presence of severe bronchiolitis, TLR4 Asp299Gly and Ile399Thr polymorphisms, anti-Ascaris IgE levels and RSV. This association should be evaluated in other populations to elucidate its role in the pathogenesis of severe bronchiolitis.</p>
</sec>
<sec sec-type="data-availability" id="s5">
<title>Data Availability Statement</title>
<p>The original contributions presented in the study are included in the article/supplementary material, further inquiries can be directed to the corresponding author.</p>
</sec>
<sec id="s6">
<title>Ethics Statement</title>
<p>The studies involving human participants were reviewed and approved by Institutional Review Board of the University of Antioquia approved the study protocol (No. 18/2015). Written informed consent to participate in this study was provided by the participants&#x00027; legal guardian/next of kin.</p>
</sec>
<sec id="s7">
<title>Author Contributions</title>
<p>All authors listed have made a substantial, direct, and intellectual contribution to the work and approved it for publication.</p>
</sec>
<sec sec-type="COI-statement" id="conf1">
<title>Conflict of Interest</title>
<p>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p>
</sec>
<sec sec-type="disclaimer" id="s8">
<title>Publisher&#x00027;s Note</title>
<p>All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.</p>
</sec> 
</body>
<back>
<ref-list>
<title>References</title>
<ref id="B1">
<label>1.</label>
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Nair</surname> <given-names>H</given-names></name> <name><surname>Nokes</surname> <given-names>DJ</given-names></name> <name><surname>Gessner</surname> <given-names>BD</given-names></name> <name><surname>Dherani</surname> <given-names>M</given-names></name> <name><surname>Madhi</surname> <given-names>SA</given-names></name> <name><surname>Singleton</surname> <given-names>RJ</given-names></name> <etal/></person-group>. <article-title>Global burden of acute lower respiratory infections due to respiratory syncytial virus in young children: a systematic review and meta-analysis</article-title>. <source>Lancet.</source> (<year>2010</year>) <volume>375</volume>:<fpage>1545</fpage>&#x02013;<lpage>55</lpage>. <pub-id pub-id-type="doi">10.1016/S0140-6736(10)60206-1</pub-id><pub-id pub-id-type="pmid">20399493</pub-id></citation></ref>
<ref id="B2">
<label>2.</label>
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hall</surname> <given-names>CB</given-names></name> <name><surname>Weinberg</surname> <given-names>GA</given-names></name> <name><surname>Blumkin</surname> <given-names>AK</given-names></name> <name><surname>Edwards</surname> <given-names>KM</given-names></name> <name><surname>Staat</surname> <given-names>MA</given-names></name> <name><surname>Schultz</surname> <given-names>AF</given-names></name> <etal/></person-group>. <article-title>Respiratory syncytial virus-associated hospitalizations among children less than 24 months of age</article-title>. <source>Pediatrics.</source> (<year>2013</year>) <volume>132</volume>:<fpage>e341</fpage>&#x02013;<lpage>8</lpage>. <pub-id pub-id-type="doi">10.1542/peds.2013-0303</pub-id><pub-id pub-id-type="pmid">23878043</pub-id></citation></ref>
<ref id="B3">
<label>3.</label>
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Buendia</surname> <given-names>JA</given-names></name> <name><surname>Patino</surname> <given-names>DG</given-names></name></person-group>. <article-title>Disability-adjusted life years for acute bronchiolitis in infants in Colombia</article-title>. <source>Pan Afr Med J.</source> (<year>2021</year>) <volume>39</volume>:<fpage>236</fpage>. <pub-id pub-id-type="doi">10.11604/pamj.2021.39.236.25761</pub-id><pub-id pub-id-type="pmid">34659609</pub-id></citation></ref>
<ref id="B4">
<label>4.</label>
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Berman</surname> <given-names>S</given-names></name></person-group>. <article-title>Epidemiology of acute respiratory infections in children of developing countries</article-title>. <source>Rev Infect Dis.</source> (<year>1991</year>) <volume>13</volume>(Suppl 6):<fpage>S454</fpage>&#x02013;<lpage>62</lpage>. <pub-id pub-id-type="doi">10.1093/clinids/13.Supplement_6.S454</pub-id><pub-id pub-id-type="pmid">1862276</pub-id></citation></ref>
<ref id="B5">
<label>5.</label>
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Buendia</surname> <given-names>JA</given-names></name> <name><surname>Patino</surname> <given-names>DG</given-names></name></person-group>. <article-title>Costs of respiratory syncytial virus hospitalizations in Colombia</article-title>. <source>Pharmacoecon Open.</source> (<year>2021</year>) <volume>5</volume>:<fpage>71</fpage>&#x02013;<lpage>6</lpage>. <pub-id pub-id-type="doi">10.1007/s41669-020-00218-7</pub-id><pub-id pub-id-type="pmid">32418086</pub-id></citation></ref>
<ref id="B6">
<label>6.</label>
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Villamil</surname> <given-names>JPS</given-names></name> <name><surname>Polack</surname> <given-names>FP</given-names></name> <name><surname>Buend&#x000ED;a</surname> <given-names>JA</given-names></name></person-group>. <article-title>Disability-adjusted life years for respiratory syncytial virus in children under 2 years</article-title>. <source>BMC Public Health.</source> (<year>2020</year>) <volume>20</volume>:<fpage>1679</fpage>. <pub-id pub-id-type="doi">10.1186/s12889-020-09796-x</pub-id><pub-id pub-id-type="pmid">33167966</pub-id></citation></ref>
<ref id="B7">
<label>7.</label>
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Welliver</surname> <given-names>RC</given-names></name></person-group>. <article-title>Review of epidemiology and clinical risk factors for severe respiratory syncytial virus (RSV) infection</article-title>. <source>J Pediatr</source>. (<year>2003</year>) <volume>143</volume>(5 Suppl):<fpage>S112</fpage>&#x02013;<lpage>7</lpage>. <pub-id pub-id-type="doi">10.1067/S0022-3476(03)00508-0</pub-id><pub-id pub-id-type="pmid">14615709</pub-id></citation></ref>
<ref id="B8">
<label>8.</label>
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Buend&#x000ED;a</surname> <given-names>JA</given-names></name> <name><surname>Patino</surname> <given-names>DG</given-names></name></person-group>. <article-title>Risk factors for severe bronchiolitis in Colombia</article-title>. <source>Trop Doct</source>. (<year>2021</year>) <volume>51</volume>:<fpage>434</fpage>&#x02013;<lpage>7</lpage>. <pub-id pub-id-type="doi">10.1177/00494755211002032</pub-id><pub-id pub-id-type="pmid">33752531</pub-id></citation></ref>
<ref id="B9">
<label>9.</label>
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Caballero</surname> <given-names>MT</given-names></name> <name><surname>Serra</surname> <given-names>ME</given-names></name> <name><surname>Acosta</surname> <given-names>PL</given-names></name> <name><surname>Marzec</surname> <given-names>J</given-names></name> <name><surname>Gibbons</surname> <given-names>L</given-names></name> <name><surname>Salim</surname> <given-names>M</given-names></name> <etal/></person-group>. <article-title>TLR4 genotype and environmental LPS mediate RSV bronchiolitis through Th2 polarization</article-title>. <source>J Clin Invest.</source> (<year>2015</year>) <volume>125</volume>:<fpage>571</fpage>&#x02013;<lpage>82</lpage>. <pub-id pub-id-type="doi">10.1172/JCI75183</pub-id><pub-id pub-id-type="pmid">25555213</pub-id></citation></ref>
<ref id="B10">
<label>10.</label>
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Zakzuk</surname> <given-names>J</given-names></name> <name><surname>Casadiego</surname> <given-names>S</given-names></name> <name><surname>Mercado</surname> <given-names>A</given-names></name> <name><surname>Alvis-Guzman</surname> <given-names>N</given-names></name> <name><surname>Caraballo</surname> <given-names>L</given-names></name></person-group>. <article-title>Ascaris lumbricoides infection induces both, reduction and increase of asthma symptoms in a rural community</article-title>. <source>Acta Trop.</source> (<year>2018</year>) <volume>187</volume>:<fpage>1</fpage>&#x02013;<lpage>4</lpage>. <pub-id pub-id-type="doi">10.1016/j.actatropica.2018.07.016</pub-id><pub-id pub-id-type="pmid">30040946</pub-id></citation></ref>
<ref id="B11">
<label>11.</label>
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ralston</surname> <given-names>SL</given-names></name> <name><surname>Lieberthal</surname> <given-names>AS</given-names></name> <name><surname>Meissner</surname> <given-names>HC</given-names></name> <name><surname>Alverson</surname> <given-names>BK</given-names></name> <name><surname>Baley</surname> <given-names>JE</given-names></name> <name><surname>Gadomski</surname> <given-names>AM</given-names></name> <etal/></person-group>. <article-title>Clinical practice guideline: the diagnosis, management, and prevention of bronchiolitis</article-title>. <source>Pediatrics.</source> (<year>2014</year>) <volume>134</volume>:<fpage>e1474</fpage>&#x02013;<lpage>502</lpage>. <pub-id pub-id-type="doi">10.1542/peds.2014-2742</pub-id><pub-id pub-id-type="pmid">26430140</pub-id></citation></ref>
<ref id="B12">
<label>12.</label>
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Legg</surname> <given-names>JP</given-names></name> <name><surname>Hussain</surname> <given-names>IR</given-names></name> <name><surname>Warner</surname> <given-names>JA</given-names></name> <name><surname>Johnston</surname> <given-names>SL</given-names></name> <name><surname>Warner</surname> <given-names>JO</given-names></name></person-group>. <article-title>Type 1 and type 2 cytokine imbalance in acute respiratory syncytial virus bronchiolitis</article-title>. <source>Am J Respir Crit Care Med.</source> (<year>2003</year>) <volume>168</volume>:<fpage>633</fpage>&#x02013;<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1164/rccm.200210-1148OC</pub-id><pub-id pub-id-type="pmid">12773328</pub-id></citation></ref>
<ref id="B13">
<label>13.</label>
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ahumada</surname> <given-names>V</given-names></name> <name><surname>Garcia</surname> <given-names>E</given-names></name> <name><surname>Dennis</surname> <given-names>R</given-names></name> <name><surname>Rojas</surname> <given-names>MX</given-names></name> <name><surname>Rondon</surname> <given-names>MA</given-names></name> <name><surname>Perez</surname> <given-names>A</given-names></name> <etal/></person-group>. <article-title>IgE responses to Ascaris and mite tropomyosins are risk factors for asthma</article-title>. <source>Clin Exp Allergy.</source> (<year>2015</year>) <volume>45</volume>:<fpage>1189</fpage>&#x02013;<lpage>200</lpage>. <pub-id pub-id-type="doi">10.1111/cea.12513</pub-id><pub-id pub-id-type="pmid">26587793</pub-id></citation></ref>
<ref id="B14">
<label>14.</label>
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Richard</surname> <given-names>K</given-names></name> <name><surname>Piepenbrink</surname> <given-names>KH</given-names></name> <name><surname>Shirey</surname> <given-names>KA</given-names></name> <name><surname>Gopalakrishnan</surname> <given-names>A</given-names></name> <name><surname>Nallar</surname> <given-names>S</given-names></name> <name><surname>Prantner</surname> <given-names>DJ</given-names></name> <etal/></person-group>. <article-title>A mouse model of human TLR4 D299G/T399I SNPs reveals mechanisms of altered LPS and pathogen responses</article-title>. <source>J Exp Med</source>. (<year>2021</year>) 218: e20200675. <pub-id pub-id-type="doi">10.1084/jem.20200675</pub-id><pub-id pub-id-type="pmid">33216117</pub-id></citation></ref>
<ref id="B15">
<label>15.</label>
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Fonceca</surname> <given-names>AM</given-names></name> <name><surname>Zosky</surname> <given-names>GR</given-names></name> <name><surname>Bozanich</surname> <given-names>EM</given-names></name> <name><surname>Sutanto</surname> <given-names>EN</given-names></name> <name><surname>Kicic</surname> <given-names>A</given-names></name> <name><surname>McNamara</surname> <given-names>PS</given-names></name> <etal/></person-group>. <article-title>Accumulation mode particles and LPS exposure induce TLR-4 dependent and independent inflammatory responses in the lung</article-title>. <source>Respir Res.</source> (<year>2018</year>) <volume>19</volume>:<fpage>15</fpage>. <pub-id pub-id-type="doi">10.1186/s12931-017-0701-z</pub-id><pub-id pub-id-type="pmid">29357863</pub-id></citation></ref>
<ref id="B16">
<label>16.</label>
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Rodriguez-Martinez</surname> <given-names>CE</given-names></name> <name><surname>Sossa-Briceno</surname> <given-names>MP</given-names></name> <name><surname>Nino</surname> <given-names>G</given-names></name></person-group>. <article-title>Predictors of prolonged length of hospital stay for infants with bronchiolitis</article-title>. <source>J Investig Med.</source> (<year>2018</year>) <volume>66</volume>:<fpage>986</fpage>&#x02013;<lpage>91</lpage>. <pub-id pub-id-type="doi">10.1136/jim-2018-000708</pub-id><pub-id pub-id-type="pmid">29588331</pub-id></citation></ref>
</ref-list>
<glossary>
<def-list>
<title>Abbreviations</title>
<def-item><term>CHD</term>
<def><p>congenital heart disease</p></def></def-item>
<def-item><term>BPD</term>
<def><p>bronchopulmonary dysplasia</p></def></def-item>
<def-item><term>PICU</term>
<def><p>pediatric intensive care unit admission</p></def></def-item>
<def-item><term>RSV</term>
<def><p>respiratory syncytial virus</p></def></def-item>
<def-item><term>NPA</term>
<def><p>nasopharyngeal aspirate.</p></def></def-item>
</def-list>
</glossary> 
</back>
</article> 